151 related articles for article (PubMed ID: 32228162)
1. Discovery of small molecule inhibitors through pharmacophore modeling, molecular docking, molecular dynamics simulation and experimental validation against myeloid cell leukemia-1 (Mcl-1).
Suleiman MR; Wang H; Huang D; Wang H; Joseph J; Huang T; Zhang F; Wang J; Cheng M
J Biomol Struct Dyn; 2021 Apr; 39(7):2512-2525. PubMed ID: 32228162
[TBL] [Abstract][Full Text] [Related]
2. In silico approaches to identify novel myeloid cell leukemia-1 (Mcl-1) inhibitors for treatment of cancer.
Ren JX; Li CP; Zhou XL; Cao XS; Xie Y
J Biomol Struct Dyn; 2018 Jul; 36(9):2424-2435. PubMed ID: 28714799
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling study of pyrrolidine derivatives as novel myeloid cell leukemia-1 inhibitors through combined 3D-QSAR, molecular docking, ADME/Tox and MD simulation techniques.
Tabti K; Baammi S; Sbai A; Maghat H; Lakhlifi T; Bouachrine M
J Biomol Struct Dyn; 2023; 41(23):13798-13814. PubMed ID: 36841617
[TBL] [Abstract][Full Text] [Related]
4. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
Zaka M; Abbasi BH; Durdagi S
J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
[TBL] [Abstract][Full Text] [Related]
5. Binding mode of Pyridoclax to myeloid cell leukemia-1 (Mcl-1) revealed by nuclear magnetic resonance spectroscopy, docking and molecular dynamics approaches.
Bourafai-Aziez A; Sebban M; Benabderrahmane M; Marekha B; Denis C; Paysant H; Weiswald LB; Carlier L; Bureau R; Coadou G; Ravault D; Voisin-Chiret AS; Sopková-de Oliveira Santos J; Oulyadi H
J Biomol Struct Dyn; 2020 Sep; 38(14):4162-4178. PubMed ID: 31612791
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
7. Design of new Mcl-1 inhibitors for cancer using fragments hybridization, molecular docking, and molecular dynamics studies.
Alzain AA; Elbadwi FA; Mukhtar RM; Shoaib TH; Abdelmoniem N; Miski SF; Ghazawi KF; Alsulaimany M; Mohamed SGA; Ainousah BE; Hussein HGA; Mohamed GA; Ibrahim SRM
J Biomol Struct Dyn; 2023 Nov; ():1-13. PubMed ID: 37962580
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Mcl-1 inhibitors through virtual screening, molecular dynamics simulations and in vitro experiments.
Yue J; Li Y; Li F; Zhang P; Li Y; Xu J; Zhang Q; Zhang C; He X; Wang Y; Liu Z
Comput Biol Med; 2023 Jan; 152():106350. PubMed ID: 36493735
[TBL] [Abstract][Full Text] [Related]
9. Ligand-based pharmacophore modeling of TNF-α to design novel inhibitors using virtual screening and molecular dynamics.
Jade DD; Pandey R; Kumar R; Gupta D
J Biomol Struct Dyn; 2022 Mar; 40(4):1702-1718. PubMed ID: 33034255
[TBL] [Abstract][Full Text] [Related]
10. Discovery of promising FtsZ inhibitors by E-pharmacophore, 3D-QSAR, molecular docking study, and molecular dynamics simulation.
Qiu Y; Zhou L; Hu Y; Bao Y
J Recept Signal Transduct Res; 2019 Apr; 39(2):154-166. PubMed ID: 31355691
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel human nicotinamide N-methyltransferase inhibitors: a structure-based pharmacophore modeling and molecular dynamics approach.
Harikrishna AS; Venkitasamy K
J Biomol Struct Dyn; 2023; 41(24):14638-14650. PubMed ID: 36856058
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore-based virtual screening, molecular docking, and molecular dynamics studies for the discovery of novel FLT3 inhibitors.
Ouassaf M; Daoui O; Alam S; Elkhattabi S; Belaidi S; Chtita S
J Biomol Struct Dyn; 2023; 41(16):7712-7724. PubMed ID: 36106982
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
14. Identification of HDAC6 selective inhibitors: pharmacophore based virtual screening, molecular docking and molecular dynamics simulation.
Yan G; Li D; Zhong X; Liu G; Wang X; Lu Y; Qin F; Guo Y; Duan S; Li D
J Biomol Struct Dyn; 2021 Apr; 39(6):1928-1939. PubMed ID: 32178584
[TBL] [Abstract][Full Text] [Related]
15. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
Melge AR; Kumar LG; K P; Nair SV; K M; C GM
J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
[TBL] [Abstract][Full Text] [Related]
16. Screening of inhibitors as potential remedial against Ebolavirus infection: pharmacophore-based approach.
Sankar M; K L; Jeyachandran S; Pandi B
J Biomol Struct Dyn; 2021 Feb; 39(2):395-408. PubMed ID: 31928158
[TBL] [Abstract][Full Text] [Related]
17. Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation.
Hou J; Zou Q; Wang Y; Gao Q; Yao W; Yao Q; Zhang J
J Biomol Struct Dyn; 2019 Aug; 37(12):3135-3149. PubMed ID: 30079817
[TBL] [Abstract][Full Text] [Related]
18. Unraveling the molecular mechanism of benzothiophene and benzofuran scaffold-merged compounds binding to anti-apoptotic Myeloid cell leukemia 1.
Marimuthu P; Singaravelu K
J Biomol Struct Dyn; 2019 May; 37(8):1992-2003. PubMed ID: 29745292
[TBL] [Abstract][Full Text] [Related]
19. Virtual screening for potential inhibitors of Mcl-1 conformations sampled by normal modes, molecular dynamics, and nuclear magnetic resonance.
Glantz-Gashai Y; Meirson T; Reuveni E; Samson AO
Drug Des Devel Ther; 2017; 11():1803-1813. PubMed ID: 28684899
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore modeling, molecular docking and molecular dynamics simulation for screening and identifying anti-dengue phytocompounds.
Vora J; Patel S; Athar M; Sinha S; Chhabria MT; Jha PC; Shrivastava N
J Biomol Struct Dyn; 2020 Apr; 38(6):1726-1740. PubMed ID: 31057055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
